Investor Relations
LifeShield Technologies is seeking mission-aligned seed investors to fund independent laboratory testing, prototype development, and intellectual-property protection for our antimicrobial gauze platform.
21,100 Lives Lost Every Day. We Are Building a Better Gauze.
The Problem: Bacterial infections kill 7.7 million people every year — more than 21,100 lives lost every single day. That is 1 in 8 deaths globally. Wound infections are a significant and preventable contributor to this crisis, and the standard wound care gauze used by clinicians and first responders has not fundamentally changed.
The Technology Platform: LifeShield is developing a proprietary antimicrobial formulation designed to be integrated directly into the fibers of gauze pads and rolled gauze — not applied as a surface coating. Our founder, U.S. Navy Veteran Dovid Ben Yehuda, brings 25 years of textile and garment manufacturing experience to this development effort, combined with a personal history of surviving sepsis from non-healing wounds now being treated by the VA.
The Initial Application: Gauze pads and rolled gauze are our first and primary product focus. This is where the need is most acute, the manufacturing pathway is most direct, and the founder's expertise is most relevant. Apparel, bedding, and other textiles are potential future applications — but gauze comes first.
The Next Milestone: Independent laboratory validation. We have not yet completed third-party testing, and we will not make performance claims until we have credible, reproducible results from accredited laboratories. This seed round funds that milestone directly.
The Future Market: A validated antimicrobial gauze platform creates a foundation for expansion into the broader antimicrobial textile market — projected to exceed $1 billion globally — including apparel, bedding, and healthcare textiles. Investors who come in at seed stage participate in the full upside of that platform.
What Sets Us Apart
Veteran-Led. Mission-Proven.
Founded by a U.S. Navy Veteran and service-connected disabled veteran with 25 years in textiles. Dovid Ben Yehuda did not find this problem in a market report — he survived it. Investors can trust that we will see this through.
Proprietary Technology Platform
Our antimicrobial formulation is proprietary, with intellectual-property protections being pursued as development progresses — creating a defensible competitive position as we move toward independent validation and commercialization.
Focused Initial Market
We are not trying to do everything at once. Gauze pads and rolled gauze are a focused, high-need starting point — used by clinicians, first responders, and patients worldwide. A validated gauze platform is the foundation for everything that follows.
Science-First Credibility
We do not make claims we cannot prove. Independent validation is our next milestone — not a future aspiration. That commitment to honest science is the foundation of trust with investors, partners, regulators, and consumers.
Where We Are Today
LifeShield Technologies is an early-stage company in active technology development. We are developing our proprietary antimicrobial formulation for gauze pads and rolled gauze, pursuing intellectual-property protections, and preparing for independent laboratory testing. We are currently seeking seed investment to fund prototype manufacturing, third-party validation, and the essential work required to advance the project responsibly toward commercialization.
Our $50,000 Funding Goal
LifeShield Technologies is seeking $50,000 in seed funding to support independent laboratory testing, prototype development, intellectual-property protection, and the essential work required to advance the project responsibly.
Priority: $50,000 Funding Needed
Fund the next critical milestone: independent validation.
This $50,000 raise supports a focused, milestone-based program: representative gauze samples, independent third-party testing, intellectual property protection, and responsible commercialization preparation.
Funding Goal
$50,000
100% Milestone-Directed
Independent testing precedes any commercial performance claims.
Founded by a U.S. Navy Veteran
LifeShield Technologies is founded and led by Dovid Ben Yehuda, a U.S. Navy Veteran and service-connected disabled veteran. As a veteran-owned small business, LifeShield is pursuing SDVOSB certification — a designation that would open access to federal contracting set-asides, VA procurement channels, and non-dilutive SBIR/STTR grant funding designed to support veteran-led innovation.
Veteran Founded
Founded and led by a U.S. Navy Veteran with 25 years of textile manufacturing experience and a personal history of surviving sepsis from service-connected wounds.
SBIR/STTR Eligible
As a small business in biotech R&D, LifeShield is eligible for SBIR and STTR grants — non-dilutive federal funding specifically for early-stage technology development.
VA Partnership Pathway
SDVOSB certification (being pursued) would create a direct pathway to VA procurement — one of the largest healthcare buyers in the world, with a mission aligned with LifeShield's.
The Window Is Open
Bacterial infections are the second leading infectious cause of death globally — and better wound care tools at the point of care remain a largely unmet need.
The global antimicrobial textile market is projected to exceed $1 billion — driven by healthcare, military, and consumer demand for passive protection integrated into everyday products.
Investing at seed stage means early equity, maximum upside, and the opportunity to shape the company's direction before the technology is validated and the market opens.

Scan to Reach Our Investor Page
Share this QR code at events, in print materials, or with your network. It links directly to this investor page so qualified contacts can learn about LifeShield and submit an inquiry instantly — no URL to type.
Get in Touch
We welcome inquiries from qualified investors. Please complete the form below and a member of our team will be in touch.